VEGI174 protein and its functional domain peptides exert antitumour effects on renal cell carcinoma

  • Authors:
    • Qiang Zhao
    • Baoan Hong
    • Tiezhu Liu
    • Yongpeng Ji
    • Xinxin Tang
    • Kan Gong
    • Lin Ye
    • Yong Yang
    • Ning Zhang
  • View Affiliations

  • Published online on: November 12, 2018     https://doi.org/10.3892/ijo.2018.4632
  • Pages: 390-398
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Vascular endothelial growth inhibitor (VEGI) has been identified as an anti‑angiogenic cytokine. However, the effects of VEGI174 protein, and its functional domain peptides V7 and V8, on renal cell carcinoma (RCC) remain unknown. In the present study, the protein and peptides were biosynthesised as experimental agents. The A498 and 786‑O RCC cell lines, and an established mouse xenograft model, were separately treated with VEGI174, V7 or V8. Cellular functions, including proliferation, migration and invasion, were subsequently detected. Cell migration and invasion were monitored using the xCELLigence system. Furthermore, tumour growth and mouse behaviours, including mobility, appetite and body weight, were assessed. The results demonstrated that VEGI174, V7 and V8 inhibited the proliferation, migration and invasion of A498 and 786‑O cell lines when administered at concentrations of 1 and 100 pM, 10 nM and 1 µM. The inhibitory effects exhibited dose‑ and time‑dependent antitumour activity. Furthermore, VEGI174, V7 and V8 inhibited tumour growth in A498 and 786‑O xenograft mice. In the A498 xenografts, the tumour growth inhibition (TGI) rates in the VEGI174‑, V7‑ and V8‑treated groups were 71, 20 and 31%, respectively. In the 786‑O xenografts, the TGI rates in the VEGI174‑, V7‑ and V8‑treated groups were 34, 26 and 31%, respectively. There was no significant loss in body weight and no cases of mortality were observed for all treated mice. In conclusion, VEGI174, V7 and V8 exhibited potential antitumour effects and were well tolerated in vivo. V7 and V8, as functional domain peptides of the VEGI174 protein, may be studied for the future treatment of RCC.
View Figures
View References

Related Articles

Journal Cover

January 2019
Volume 54 Issue 1

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Zhao, Q., Hong, B., Liu, T., Ji, Y., Tang, X., Gong, K. ... Zhang, N. (2019). VEGI174 protein and its functional domain peptides exert antitumour effects on renal cell carcinoma. International Journal of Oncology, 54, 390-398. https://doi.org/10.3892/ijo.2018.4632
MLA
Zhao, Q., Hong, B., Liu, T., Ji, Y., Tang, X., Gong, K., Ye, L., Yang, Y., Zhang, N."VEGI174 protein and its functional domain peptides exert antitumour effects on renal cell carcinoma". International Journal of Oncology 54.1 (2019): 390-398.
Chicago
Zhao, Q., Hong, B., Liu, T., Ji, Y., Tang, X., Gong, K., Ye, L., Yang, Y., Zhang, N."VEGI174 protein and its functional domain peptides exert antitumour effects on renal cell carcinoma". International Journal of Oncology 54, no. 1 (2019): 390-398. https://doi.org/10.3892/ijo.2018.4632